Literature DB >> 12531178

HIV mutagenesis and the evolution of antiretroviral drug resistance.

Louis M Mansky1.   

Abstract

The development of antiretroviral drug resistance is a major threat to the effective treatment of human immunodeficiency virus type 1 (HIV-1) infection. Drug treatment failure is associated with accumulation of drug resistance mutations and the evolution of drug resistance. Studies from microbial systems provide evidence for a correlation between drug resistance development and increased pathogen mutation rates. Recent studies with HIV-1 have shown that drugs targeted against reverse transcriptase (RT) as well as drug-resistant RT can increase HIV-1 mutation frequencies. Furthermore, combinations of drug and drug-resistant RT have been found to increase virus mutation frequencies in a multiplicative manner. The correlation of increased HIV-1 mutation rates with the evolution of antiretroviral drug resistance indicates that drug failure could increase the likelihood of further resistance evolving from subsequent drug regimens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12531178     DOI: 10.1016/s1368-7646(02)00118-8

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  20 in total

1.  Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.

Authors:  Bettina C Fries; Emily Cook; Xiabo Wang; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Resistance evolution in HIV - modeling when to intervene.

Authors:  Liliana Mabel Peinado Cortes; Ryan Zurakowski
Journal:  Proc Am Control Conf       Date:  2012

Review 3.  Potential implication of residual viremia in patients on effective antiretroviral therapy.

Authors:  Gautam K Sahu
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

4.  Transmembrane protein aptamers that inhibit CCR5 expression and HIV coreceptor function.

Authors:  Elizabeth H Scheideman; Sara A Marlatt; Yanhua Xie; Yani Hu; Richard E Sutton; Daniel DiMaio
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

5.  Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain.

Authors:  Philippe Lemey; Inge Derdelinckx; Andrew Rambaut; Kristel Van Laethem; Stephanie Dumont; Steve Vermeulen; Eric Van Wijngaerden; Anne-Mieke Vandamme
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Interrelationship between cytoplasmic retroviral Gag concentration and Gag-membrane association.

Authors:  Keir H Fogarty; Serkan Berk; Iwen F Grigsby; Yan Chen; Louis M Mansky; Joachim D Mueller
Journal:  J Mol Biol       Date:  2013-12-04       Impact factor: 5.469

7.  Evolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism.

Authors:  Wendy Maury; Robert J Thompson; Quentin Jones; Sarahann Bradley; Tara Denke; Prasith Baccam; Matthew Smazik; J Lindsay Oaks
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

8.  Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA).

Authors:  Devendra K Dhaked; Jitender Verma; Anil Saran; Evans C Coutinho
Journal:  J Mol Model       Date:  2008-12-02       Impact factor: 1.810

9.  Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.

Authors:  Brian M Jones; Susan Ss Chiu; Wilfred Hs Wong; Wilina Wl Lim; Yu-Lung Lau
Journal:  J Int AIDS Soc       Date:  2005-05-03       Impact factor: 5.396

Review 10.  The utilization of humanized mouse models for the study of human retroviral infections.

Authors:  Rachel Van Duyne; Caitlin Pedati; Irene Guendel; Lawrence Carpio; Kylene Kehn-Hall; Mohammed Saifuddin; Fatah Kashanchi
Journal:  Retrovirology       Date:  2009-08-12       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.